Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Study to Compare Progression-free Survival in Patients With HER2 Positive Metastatic Breast Cancer Who Continue or Discontinue Herceptin in Combination With 2nd Line Chemotherapy, Having Progressed on 1st Line Chemotherapy in Combination With Herceptin

NCT00448279 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00448279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00448279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Study to Compare Progression-free Survival in Patients With HER2 Positive Metastatic Breast Cancer Who Continue or Discontinue Herceptin in Combination With 2nd Line Chemotherapy, Having Progressed on 1st Line Chemotherapy in Combination With Herceptin
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2007
Completion date
September 30, 2010
Enrollment
58 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer